$RGNX
REGENXBIO Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020022890 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $17.64M $884.0K
YoY Change 1895.93% -99.33%
Cost Of Revenue $3.409M $29.00K
YoY Change 11655.17% -98.8%
Gross Profit $14.24M $855.0K
YoY Change 1564.91% -99.34%
Gross Profit Margin 80.68% 96.72%
Selling, General & Admin $14.80M $11.60M
YoY Change 27.59% 38.1%
% of Gross Profit 103.97% 1356.73%
Research & Development $37.04M $25.20M
YoY Change 46.95% 28.92%
% of Gross Profit 260.17% 2947.72%
Depreciation & Amortization $2.000M $1.600M
YoY Change 25.0% 100.0%
% of Gross Profit 14.05% 187.13%
Operating Expenses $37.04M $25.20M
YoY Change 46.95% 28.92%
Operating Profit -$37.70M -$35.91M
YoY Change 5.0% -135.19%
Interest Expense -$2.300M $3.600M
YoY Change -163.89% 63.64%
% of Operating Profit
Other Income/Expense, Net $3.608M
YoY Change 62.96%
Pretax Income -$40.04M -$32.30M
YoY Change 23.96% -130.98%
Income Tax $0.00 $70.00K
% Of Pretax Income
Net Earnings -$40.04M -$32.23M
YoY Change 24.23% -130.92%
Net Earnings / Revenue -226.92% -3645.7%
Basic Earnings Per Share -$1.08 -$0.89
Diluted Earnings Per Share -$1.08 -$0.89
COMMON SHARES
Basic Shares Outstanding 36.37M
Diluted Shares Outstanding 36.37M

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $279.3M $285.2M
YoY Change -2.07% 24.05%
Cash & Equivalents $69.41M $55.85M
Short-Term Investments $209.8M $229.4M
Other Short-Term Assets $14.40M $10.30M
YoY Change 39.81% 49.28%
Inventory
Prepaid Expenses
Receivables $44.50M $8.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $338.2M $303.9M
YoY Change 11.29% 15.68%
LONG-TERM ASSETS
Property, Plant & Equipment $30.41M $23.14M
YoY Change 31.43% 56.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $77.40M $159.1M
YoY Change -51.35% 2596.61%
Other Assets $4.200M $3.300M
YoY Change 27.27% 200.0%
Total Long-Term Assets $125.7M $215.1M
YoY Change -41.56% 294.68%
TOTAL ASSETS
Total Short-Term Assets $338.2M $303.9M
Total Long-Term Assets $125.7M $215.1M
Total Assets $463.9M $519.0M
YoY Change -10.62% 63.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.000M $4.200M
YoY Change 114.29% -16.0%
Accrued Expenses $22.80M $15.50M
YoY Change 47.1% 56.57%
Deferred Revenue $600.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.80M $21.40M
YoY Change 48.6% 43.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.00M $1.772M
YoY Change 577.2% -0.23%
Total Long-Term Liabilities $12.00M $1.772M
YoY Change 577.2% -0.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.80M $21.40M
Total Long-Term Liabilities $12.00M $1.772M
Total Liabilities $43.80M $31.98M
YoY Change 36.97% 78.65%
SHAREHOLDERS EQUITY
Retained Earnings -$217.9M -$115.3M
YoY Change 88.96%
Common Stock $638.6M $602.4M
YoY Change 6.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $420.2M $487.1M
YoY Change
Total Liabilities & Shareholders Equity $463.9M $519.0M
YoY Change -10.61% 63.63%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$40.04M -$32.23M
YoY Change 24.23% -130.92%
Depreciation, Depletion And Amortization $2.000M $1.600M
YoY Change 25.0% 100.0%
Cash From Operating Activities -$35.57M -$29.30M
YoY Change 21.42% -150.4%
INVESTING ACTIVITIES
Capital Expenditures $4.630M $2.455M
YoY Change 88.59% 4.74%
Acquisitions
YoY Change
Other Investing Activities $37.30M $7.900M
YoY Change 372.15% -122.77%
Cash From Investing Activities $32.71M $5.461M
YoY Change 498.96% -114.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.761M 4.127M
YoY Change -33.1% -0.94%
NET CHANGE
Cash From Operating Activities -35.57M -29.30M
Cash From Investing Activities 32.71M 5.461M
Cash From Financing Activities 2.761M 4.127M
Net Change In Cash -103.0K -19.71M
YoY Change -99.48% -178.17%
FREE CASH FLOW
Cash From Operating Activities -$35.57M -$29.30M
Capital Expenditures $4.630M $2.455M
Free Cash Flow -$40.20M -$31.75M
YoY Change 26.62% -156.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
450197000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25203000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11558000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4555000
CY2019Q4 us-gaap Assets
Assets
497908000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1330000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6409000
CY2019Q4 rgnx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
24846000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10078000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33676000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3333000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36992000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36992000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
627810000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
205000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177822000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
497908000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
884000
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7990000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37190000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37190000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
638588000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-580000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217860000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
420152000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
463936000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17644000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3409000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37035000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14833000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37700000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35906000
CY2020Q1 rgnx Interest Income From Licencing
InterestIncomeFromLicencing
848000
CY2019Q1 rgnx Interest Income From Licencing
InterestIncomeFromLicencing
613000
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-3186000
CY2019Q1 us-gaap Investment Income Net
InvestmentIncomeNet
2995000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
70000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37104000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36366000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
450197000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2154000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
607000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8017000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-785000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40038000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
420152000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
508848000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3762000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
365000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5718000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
621000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-32228000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
487053000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-40038000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-32228000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8017000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5718000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-39000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
368000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1994000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1614000
CY2020Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
7085000
CY2020Q1 rgnx Imputed Interest Income From Licensing
ImputedInterestIncomeFromLicensing
848000
CY2019Q1 rgnx Imputed Interest Income From Licensing
ImputedInterestIncomeFromLicensing
613000
CY2020Q1 us-gaap Available For Sale Equity Securities Gross Unrealized Loss
AvailableForSaleEquitySecuritiesGrossUnrealizedLoss
12196000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25000
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-327000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5744000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-591000
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
947000
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
790000
CY2020Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2833000
CY2019Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
295000
CY2020Q1 rgnx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-703000
CY2019Q1 rgnx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-573000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1705000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-26000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3063000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
316000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3813000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2932000
CY2020Q1 rgnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-851000
CY2019Q1 rgnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-592000
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1156000
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-644000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35573000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29297000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
30692000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
79249000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
60907000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
87165000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
7124000
CY2020Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.</p>
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69411000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55852000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1330000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1053000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70741000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56905000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4630000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2455000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32709000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5461000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2154000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3762000
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
607000
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
365000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2761000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4127000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-103000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19709000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70844000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76614000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70741000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56905000
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company’s proprietary adeno-associated virus (AAV) gene delivery platform (NAV Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The NAV® Technology Platform is being applied by the Company, as well as by third-party licensees (NAV Technology Licensees), in the development of a broad pipeline of product candidates in multiple therapeutic areas. Additionally, the NAV Technology Platform is currently being applied in one commercially available product, Zolgensma®, which is marketed by a NAV Technology Licensee. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Risks </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020, the Company had generated an accumulated deficit of $217.9 million since inception. As the Company has incurred cumulative losses since inception, transition to recurring profitability is dependent upon achieving a level of revenues adequate to support the Company’s cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, the Company will continue to need to raise additional capital, to the extent possible.<span style="color:#000000;"> As of March 31, 2020, the Company had cash, cash equivalents and marketable securities of $356.6 million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical trials, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to transition from clinical manufacturing to the commercial production of products.</p>
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217900000
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
356600000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements. Significant estimates are used in the following areas, among others: license and royalty revenue, stock-based compensation expense, accrued research and development expenses and other accrued liabilities, income taxes and the fair value of financial instruments.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the impact of the novel coronavirus (COVID-19) pandemic on its business, results of operations and financial condition. The full extent to which COVID-19 will directly or indirectly impact the Company’s business, results of operations and financial condition in the future is unknown at this time and will depend on future developments that are highly unpredictable. The most significant estimates affecting the Company’s consolidated financial statements that may be impacted by the COVID-19 pandemic are related to the Company’s assessment of credit losses on accounts receivable, contract assets and available-for-sale debt securities.</p>
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
267339000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20598000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
730000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
287207000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
297631000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32884000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
34000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
330481000
CY2020Q1 rgnx Available For Sale Debt Securities Remaining Maturities Greater Than Three Years
AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears
0
CY2019Q4 rgnx Available For Sale Debt Securities Remaining Maturities Greater Than Three Years
AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears
0
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-800000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1000000.0
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
90352000
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
730000
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
90352000
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
730000
CY2019Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
61118000
CY2019Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
34000
CY2019Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
61118000
CY2019Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
34000
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
30
CY2020Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q1 rgnx Non Marketable Equity Securities
NonMarketableEquitySecurities
400000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
287207000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
330481000
CY2020Q1 rgnx Non Marketable Equity Securities Carrying Value
NonMarketableEquitySecuritiesCarryingValue
0
CY2019Q4 rgnx Non Marketable Equity Securities Carrying Value
NonMarketableEquitySecuritiesCarryingValue
0
CY2020Q1 rgnx Remeasurements Or Impairment Losses On Non Marketable Equity Securities
RemeasurementsOrImpairmentLossesOnNonMarketableEquitySecurities
0
CY2019Q1 rgnx Remeasurements Or Impairment Losses On Non Marketable Equity Securities
RemeasurementsOrImpairmentLossesOnNonMarketableEquitySecurities
0
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43311000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16295000
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46709000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14338000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30414000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28973000
CY2020Q1 rgnx Milestone Fee Payments Upon Submission Preclinical Filings
MilestoneFeePaymentsUponSubmissionPreclinicalFilings
300000
CY2020Q1 rgnx Milestone Fee Payments Upon Commencement Of Clinical Trials
MilestoneFeePaymentsUponCommencementOfClinicalTrials
24100000
CY2020Q1 rgnx Milestone Fee Payments Upon Submission Of Regulatory Approval Filings
MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings
31000000.0
CY2020Q1 rgnx Milestone Fee Payments Upon Approval Of Commercial Products
MilestoneFeePaymentsUponApprovalOfCommercialProducts
109000000.0
CY2020Q1 rgnx Milestone Fee Payments Upon Achievement Of Specified Sales Targets
MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets
207000000.0
CY2019Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
42303000
CY2020Q1 rgnx Additions Related To Accounts Receivable
AdditionsRelatedToAccountsReceivable
18142000
CY2020Q1 rgnx Deductions Related To Accounts Receivable
DeductionsRelatedToAccountsReceivable
-11550000
CY2020Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
48895000
CY2020Q1 rgnx Additions Related To Contract With Customer Assets
AdditionsRelatedToContractWithCustomerAssets
350000
CY2020Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
350000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3333000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3333000
CY2018Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
31599000
CY2019Q1 rgnx Additions Related To Accounts Receivable
AdditionsRelatedToAccountsReceivable
1738000
CY2019Q1 rgnx Deductions Related To Accounts Receivable
DeductionsRelatedToAccountsReceivable
-2207000
CY2019Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
31130000
CY2018Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
750000
CY2019Q1 rgnx Additions Related To Contract With Customer Assets
AdditionsRelatedToContractWithCustomerAssets
1000000
CY2019Q1 rgnx Deductions Related To Contract With Customer Asset
DeductionsRelatedToContractWithCustomerAsset
-750000
CY2019Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1000000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3933000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3933000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3300000
CY2020Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
48900000
CY2020Q1 us-gaap Billed Contract Receivables
BilledContractReceivables
7100000
CY2020Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
41800000
CY2019Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
42300000
CY2019Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
400000
CY2019Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
41900000
CY2020Q1 rgnx Capitalized Contract Cost Credit Loss
CapitalizedContractCostCreditLoss
0
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9978000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8017000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5718000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
82400000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8017000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5718000
CY2020Q1 rgnx Proceeds From Stock Options Exercised Including Unsettled Options
ProceedsFromStockOptionsExercisedIncludingUnsettledOptions
2300000
CY2020Q1 rgnx Cares Act Of2020 Elimination Of Net Operating Loss Deductions As Percentage Of Taxable Income
CARESActOf2020EliminationOfNetOperatingLossDeductionsAsPercentageOfTaxableIncome
0.80
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6696000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10903000
CY2020Q1 rgnx Accrued Sublicense Fees And Royalties On Reagent Sales
AccruedSublicenseFeesAndRoyaltiesOnReagentSales
5112000
CY2019Q4 rgnx Accrued Sublicense Fees And Royalties On Reagent Sales
AccruedSublicenseFeesAndRoyaltiesOnReagentSales
4542000
CY2020Q1 rgnx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
5089000
CY2019Q4 rgnx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
5791000
CY2020Q1 rgnx Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
622000
CY2019Q4 rgnx Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
1328000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2020Q1 rgnx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
20327000
CY2019Q4 rgnx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
24846000

Files In Submission

Name View Source Status
0001564590-20-022890-index-headers.html Edgar Link pending
0001564590-20-022890-index.html Edgar Link pending
0001564590-20-022890.txt Edgar Link pending
0001564590-20-022890-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgnx-10q_20200331.htm Edgar Link pending
rgnx-10q_20200331_htm.xml Edgar Link completed
rgnx-20200331.xsd Edgar Link pending
rgnx-20200331_cal.xml Edgar Link unprocessable
rgnx-20200331_def.xml Edgar Link unprocessable
rgnx-20200331_lab.xml Edgar Link unprocessable
rgnx-20200331_pre.xml Edgar Link unprocessable
rgnx-ex311_50.htm Edgar Link pending
rgnx-ex312_52.htm Edgar Link pending
rgnx-ex321_51.htm Edgar Link pending
Show.js Edgar Link pending